Cargando…

Triple-Negative Breast Cancer

Detalles Bibliográficos
Autores principales:	Chu, Quyen D., King, Tari, Hurd, Thelma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357518/ https://www.ncbi.nlm.nih.gov/pubmed/22649738 http://dx.doi.org/10.1155/2012/671684

Ejemplares similares

Outcome for Patients with Triple-Negative Breast Cancer Is Not Dependent on Race/Ethnicity
por: Chu, Quyen D., et al.
Publicado: (2012)

Metronomic chemotherapy for triple negative breast cancer?
por: Di Desidero, Teresa, et al.
Publicado: (2016)

Stratifying the stratifiers of triple negative breast cancer
por: Wang, Dong-Yu, et al.
Publicado: (2020)

Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer
por: Hiller, David J., et al.
Publicado: (2012)

Triple negative breast cancer: A continuing challenge
por: Gupta, Sudeep
Publicado: (2013)

Targeting MYC for triple-negative breast cancer treatment
por: Klauber-DeMore, Nancy, et al.
Publicado: (2018)

Sacituzumab govitecan in triple-negative breast cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Stratifying triple-negative breast cancer: which definition(s) to use?
por: Adamo, Barbara, et al.
Publicado: (2011)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Using interferon-beta to combat cancer stem cell properties in triple negative breast cancer
por: Doherty, Mary R., et al.
Publicado: (2018)

Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology
por: Vidula, Neelima, et al.
Publicado: (2017)

Sacituzumab govitecan: ascending the treatment algorithm in triple negative breast cancer
por: Rozenblit, Mariya, et al.
Publicado: (2022)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

Targeting BCL6 and STAT3 in triple negative breast cancer: the one-two punch?
por: Walker, Sarah R., et al.
Publicado: (2015)

Novel Biomarkers to Guide Immunotherapy De-Escalation in the Neoadjuvant Setting in Triple-Negative Breast Cancer
por: Gandhi, Shipra
Publicado: (2023)

Molecular Characteristics and Metastasis Predictor Genes of Triple-Negative Breast Cancer: A Clinical Study of Triple-Negative Breast Carcinomas
por: Kuo, Wen-Hung, et al.
Publicado: (2012)

Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy
por: Walsh, Elaine M., et al.
Publicado: (2018)

Treatment response in triple-negative breast cancer: a role for eEF2 kinase-mediated autophagy?
por: Ho, Cally J., et al.
Publicado: (2020)

Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?
por: Franzoi, Maria Alice, et al.
Publicado: (2020)

Overview of triple negative breast cancer prognostic signatures in the context of data science-driven clinico-genomics research
por: Capobianco, Enrico
Publicado: (2022)

Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
por: Maltoni, Roberta, et al.
Publicado: (2022)

Molecular characteristics of recurrent triple-negative breast cancer
por: TSAI, CHUNG-HSIN, et al.
Publicado: (2015)

Characteristics of triple-negative breast cancer
por: de Ruijter, Tim C., et al.
Publicado: (2010)

Triple Negative Breast Cancer – An Overview
por: Aysola, Kartik, et al.
Publicado: (2013)

Male Triple-Negative Breast Cancer
por: Qavi, Qasif, et al.
Publicado: (2021)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

Theranostics for Triple-Negative Breast Cancer
por: Choi, Hyeryeon, et al.
Publicado: (2023)

MicroRNAs and Triple Negative Breast Cancer
por: D’Ippolito, Elvira, et al.
Publicado: (2013)

Metabolic characterization of triple negative breast cancer
por: Cao, Maria D, et al.
Publicado: (2014)

Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer
por: Qiu, Jingdan, et al.
Publicado: (2016)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
por: Brandão, Mariana, et al.
Publicado: (2019)

Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer
por: Li, Chia-Jung, et al.
Publicado: (2021)

The Triple-Negative Breast Cancer Database: an omics platform for reference, integration and analysis of triple-negative breast cancer data
por: Raju, Rajesh, et al.
Publicado: (2014)

LncRNAs as new biomarkers to differentiate triple negative breast cancer from non-triple negative breast cancer
por: Lv, Mingming, et al.
Publicado: (2016)

Revealing targeted therapeutic opportunities in triple-negative breast cancers: A new strategy
por: Poage, Graham M, et al.
Publicado: (2013)

Dynamin 2, cell trafficking, and the triple-negative paradox
por: Chernikova, Sophia B., et al.
Publicado: (2019)

Milking the stroma in triple-negative breast cancer
por: Thompson, Alastair M., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_vpgo7o9a62q93nuplrhieg3o2p